Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems

Toxicology and Applied Pharmacology

Volumn 250, Issue 3, 2011, Pages 312-321

  Fanzani, Alessandro ^a   Zanola, Alessandra ^a   Rovetta, Francesca ^a   Rossi, Stefania ^a   Aleo, Maria Francesca ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Akt; Atrophy; Autophagy; Cisplatin; Myoblasts; Proteasome

Indexed keywords

ATROGIN 1; BECLIN 1; CISPLATIN; INSULIN; PROTEASOME; PROTEIN BNIP3; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; BODY SIZE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATROPHY; AUTOPHAGY; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MUSCLE FIBERS, SKELETAL; MYOBLASTS; NECROSIS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 78651468365     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.11.003     Document Type: Article

References (64)

1. Acharyya S., Guttridge D.C. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin. Cancer Res. 2007, 13:1356-1361.
2. Aucello M., Dobrowolny G., Musarò A. Localized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway. Autophagy 2009, 5:527-529.
3. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008, 6:1-18.
4. Bechet D., Tassa A., Combaret L., Taillandier D., Attaix D. Regulation of skeletal muscle proteolysis by amino acids. J. Ren. Nutr. 2005, 15:18-22.
5. Bechet D., Tassa A., Taillandier D., Combaret L., Attaix D. Lysosomal proteolysis in skeletal muscle. Int. J. Biochem. Cell Biol. 2005, 37:2098-2114.
6. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
7. Bodine S.C., Stitt T.N., Gonzales M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3:1014-1019.
8. Bonetto A., Penna F., Muscaritoli M., Minero V.G., Rossi Fanelli F., Baccino F.M., Costelli P. Are antioxidants useful for treating skeletal muscle atrophy?. Free Radic. Biol. Med. 2009, 47:906-916.
9. Boulikas T., Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 2003, 10:1663-1682.
10. Bursch W. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ. 2001, 8:569-581.
11. Cao P.R., Kim H.J., Lecker S.H. Ubiquitin-protein ligases in muscle wasting. Int. J. Biochem. Cell Biol. 2005, 37:2088-2097.
12. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp. Toxicol. Pathol. 2009, 61:223-242.
13. Costelli P., Reffo P., Penna F., Autelli R., Bonelli G., Baccino F.M. Ca2+-dependent proteolysis in muscle wasting. Int. J. Biochem. Cell Biol. 2005, 37:2134-2146.
14. Damrauer J.S., Stadler M.E., Acharyya S., Baldwin A.S., Couch M.E., Guttridge D.C. Chemothrapy-induced muscle wasting: association with NF-kB and cancer cachexia. Basic Appl. Myol. 2008, 18:139-148.
15. Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., Rosenthal N., Molinaro M., Protasi F., Fanò G., Sandri M., Musarò A. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008, 8:425-436.
16. Frankfurt O.S., Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J. Histochem. Cytochem. 2001, 49:369-378.
17. Glass D.J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 2003, 5:87-90.
18. Glass D.J. Molecular mechanisms modulating muscle mass. Trends Mol. Med. 2003, 9:344-350.
19. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA 2001, 98:14440-14445.
20. Gozuacik D., Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004, 23:2891-2906.
21. Jagoe R.T., Goldberg A.L. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?. Curr. Opin. Clin. Nutr. Metab. Care 2001, 4:183-190.
22. Jagoe R.T., Lecker S.H., Gomes M., Goldberg A.L. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J. 2002, 16:1697-1712.
23. Jo S., Cho W.Y., Sung S.A., Kim H.K., Won N.H. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005, 67:458-466.
24. Kabeya Y., Mizushima N., Yamamoto A., Oshitani-Okamoto S., Ohsumi Y., Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J. Cell Sci. 2004, 117:2805-2812.
25. Kandarian S.C., Jackman R.W. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 2006, 33:155-165.
26. Lecker S.H., Solomon V., Mitch W.E., Goldberg A.L. Muscle protein breakdown and the critical role of the Ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 1999, 129:227S-237S.
27. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., Price S.R., Mitch W.E., Goldberg A.L. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004, 18:39-51.
28. Lecker S.H., Goldberg A.L., Mitch W.E. Protein degradation by the Ubiquitin-proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 2006, 17:1807-1819.
29. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
30. Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., Burden S.J., Di Lisi R., Sandri C., Zhao J., Goldberg A.L., Schiaffino S., Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007, 6:458-471.
31. Mammucari C., Schiaffino S., Sandri M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008, 4:524-526.
32. Martinet W., De Meyer G.R., Herman A.G., Kockx M.M. Amino acid deprivation induces both apoptosis and autophagy in murine C2C12 muscle cells. Biotechnol. Lett. 2005, 27:1157-1163.
33. Martinet W., De Meyer G.R., Andries L., Herman A.G., Kockx M.M. In situ detection of starvation-induced autophagy. J. Histochem. Cytochem. 2006, 54:85-96.
34. Masiero E., Sandri M. Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 2010, 6:307-309.
35. Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 1996, 335:1897-1905.
36. Mizushima N., Ohsumi Y., Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct. Funct. 2002, 27:421-429.
37. Moylan J.S., Reid M.B. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve 2007, 35:411-429.
38. Munafò D.B., Colombo M.I. A novel assay to study autophagy: regulation of autophagosome vacuole size by aminoacid deprivation. J. Cell Sci. 2001, 114:3619-3629.
39. Musarò A., Fulle S., Fanò G. Oxidative stress and muscle homeostasis. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:236-242.
40. Nishikawa M., Nagatomi H., Chang B., Sato E., Inoue M. Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction induced by cisplatin. Arch. Biochem. Biophys. 2001, 1:78-84.
41. Periyasami-Thandavan S., Jing M., Wei Q., Smith R., Yin X., Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 2008, 74:631-640.
42. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
43. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3:1009-1013.
44. Sacheck J.M., Hyatt J.P., Raffaello A., Jagoe R.T., Roy R.R., Edgerton V.R., Lecker S.H., Goldberg A.L. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 2007, 21:140-155.
45. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
46. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., Goldberg A.L. FoxO transcription factors induce the atrophy-related Ubiquitin Ligase Atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
47. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
48. Smith D.M., Patel S., Raffoul F., Haller E., Mills G.B., Nanjundan M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ. 2010, 17(12):1867-1881.
49. Sorokin A.V., Kim E.R., Ovchinnikov L.P. Proteasome system of protein degradation and processing. Biochemistry (Moscow) 2009, 74:1411-1442.
50. Sou Y., Tanida I., Komatsu M., Ueno T., Kominami E. Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J. Biol. Chem. 2006, 281:3017-3024.
51. Stephens N.A., Skipworth R.J., Fearon K.C. Cachexia, survival and the acute phase response. Curr. Opin. Support. Palliat. Care 2008, 2:267-274.
52. Taguchi T., Nazneen A., Abid M.R., Razzaque M.S. Cisplatin associated nephrotoxicity and pathological events. Contrib. Nephrol. 2005, 148:107-121.
53. Tanida I., Wakabayashi M., Kanematsu T., Minematsu-Ikeguchi N., Sou Y., Hirata M., Ueno T., Kominami E. Lysosomal turnover of GABARAP-phospholipid conjugate is activated during differentiation of C2C12 cells to myotubes without inactivation of the mTor kinase-signaling pathway. Autophagy 2006, 2:264-271.
54. Tisdale M.J. Cachexia in cancer patients. Nat. Rev. Cancer 2002, 2:862-871.
55. Tisdale M.J. Cancer cachexia. Curr. Opin. Gastroenterol. 2010, 26:146-151.
56. Villalobos J.C., Mora R., Lomonte B., Gutiérrez J.M., Angulo Y. Cytotoxicity induced in myotubes by a Lys49 phospholipase A2 homologue from the venom of the snake Bothrops asper: evidence of rapid plasma membrane damage and a dual role for extracellular calcium. Toxicol. In Vitro 2007, 21:1382-1389.
57. Wang G., Hallberg L.M., Englander E.W. Rapid SINE-mediated detection of cisplatin: DNA adduct formation in vitro and in vivo in blood. Mutat. Res. 1999, 434:67-74.
58. Wang L., Chanvorachote P., Toledo D., Stehlik C., Mercer R.R., Castranova V., Rojanasakul Y. Peroxide is a key mediator of Bcl-2 down-regulation and apoptosis induction by cisplatin in human lung cancer cells. Mol. Pharmacol. 2008, 73:119-127.
59. Yaffe D., Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270:725-727.
60. Yang C., Kaushal V., Shash S.V., Kaushal G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am. J. Physiol. Ren. Physiol. 2008, 294:F777-F787.
61. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
62. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. Biochem. Biophys. Res. Commun. 2004, 313:453-458.
63. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., Lecker S.H., Goldberg A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6:472-483.
64. Zhao J., Brault J.J., Schild A., Goldberg A.L. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 2008, 4:378-380.